Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04679870




Registration number
NCT04679870
Ethics application status
Date submitted
17/12/2020
Date registered
22/12/2020
Date last updated
3/04/2024

Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
Scientific title
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
Secondary ID [1] 0 0
2020-003087-45
Secondary ID [2] 0 0
MYLOX-1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelofibrosis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GB2064

Experimental: GB2064 - GB2064 will be administered orally as 4 x 250 mg tablets twice a day.


Treatment: Drugs: GB2064
GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and tolerability of GB2064: AE
Timepoint [1] 0 0
9 Months

Eligibility
Key inclusion criteria
Participants must satisfy all of the following criteria at the Screening visit:

1. Adult male or female participants = 18 years of age at enrolment:

1. Female participants may be of non-childbearing potential defined as permanently
sterile or postmenopausal, or female participants considered to be of
childbearing potential who agree to use highly effective birth control methods
until 90 days after the follow-up visit. Female participants should refrain from
ova donation from the date of Enrolment (Day -1) until 90 days after the
follow-up visit.

2. Male participants will agree to use contraception throughout the study and until
90-days after the Follow-up visit. Male participants must agree to refrain from
sperm donation from the date of Enrolment (Day -1) until 90 days after the
follow-up visit.

2. Diagnosis of PMF or SMF with intermediate -2 or high-risk disease according to the
Dynamic International Prognostic Scoring System (DIPSS)-plus or if with low risk
disease then with symptomatic splenomegaly as defined by sonographic assessment as
spleen length of >12 cm or by physical examination as = 5 cm below left costal margin.

3. Participants who are not currently taking a Janus kinase (JAK) inhibitor (e.g.
ruxolitinib or fedratinib) and are therefore refractory, intolerant or ineligible for
a JAK inhibitor according to appropriate guidelines (including local guidelines).

4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

5. Required baseline laboratory status:

1. Absolute platelet count (APC) = 50 x 109/L

2. Absolute neutrophil count (ANC) = 1.5 x 109/L (1500/mm3)

3. Serum direct bilirubin = 2.0 x ULN (upper limit of normal)

4. AST (SGOT) or ALT (SGPT) [if both measured, then this applies to both
measurements] = 2.5 x ULN, except for participants with MF involvement of the
liver who must have levels = 5 x ULN

5. Estimated Glomerular Filtration Rate (eGFR) or creatinine clearance (CrCl) (CrCl
calculated by the Cockroft and Gault method) = 30 ml/min/1.73 m2.

6. Peripheral blood blasts <10%

6. Treatment-related toxicities from prior therapies must have resolved to Common
Terminology Criteria for Adverse Events (CTCAE) Grade = 1.

7. Participants must have a documented history of transfusion records (if there have been
any such transfusions) in the preceding 12 weeks to Day 1.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Current treatment with a JAK inhibitor (e.g. ruxolitinib or fedratinib) or a history
of treatment with a JAK inhibitor within two weeks of enrolment.

2. Positive hepatitis panel and/or positive HIV test.

3. Any concurrent severe and/or uncontrolled medical conditions that could increase the
participant's risk for toxicity while in the study or that could confound
discrimination between disease- and study treatment-related toxicities. Any planned
major surgery during the study period

4. Impaired cardiac function or clinically significant cardiac diseases, including any of
the following:

1. History or presence of ventricular tachyarrhythmia.

2. Presence of unstable atrial fibrillation (ventricular response > 100 bpm);
Participants with stable atrial fibrillation are eligible, provided they do not
meet any of the other cardiac exclusion criteria.

3. Clinically significant resting bradycardia (< 50 bpm) and use of a cardiac
pacemaker or implantable cardioverter defibrillator.

4. Angina pectoris or acute myocardial infarction = 90 days prior to starting study
drug.

5. Other clinically significant heart disease (e.g., symptomatic congestive heart
failure; uncontrolled arrhythmia or hypertension; history of labile hypertension
or poor compliance with an antihypertensive regimen).

5. Participants who are currently receiving chronic (> 14 days) treatment with
corticosteroids at a dose > 10 mg of prednisone (or its glucocorticoid equivalent) per
day, or any other chronic immunosuppressive treatment that cannot be discontinued
prior to starting study drug.

6. Participants with impairment of gastrointestinal (GI) function or GI disease that may
significantly alter the absorption of GB2064 as per physician's opinion.

7. Participants who received radiotherapy within the last month prior to screening
procedures, or patients who received splenectomy in the previous three months or are
scheduled for the procedure in the next three months.

8. Participants who had a history of malignancy in the past 3 years, except for treated
early stage squamous, basal cell carcinoma or treated, localised prostate cancer.

9. Presence of clinically meaningful active bacterial, fungal, parasitic or viral
infection which requires therapy.

10. Previous history of Progressive Multifocal Leuko-encephalopathy (PML).

11. Pregnant or breast feeding (lactating) women, where pregnancy is defined as the state
of a female after conception and until the termination of gestation, confirmed by a
positive ß- HCG laboratory test.

12. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using highly effective methods of contraception
during dosing and for 90 days after study treatment. Highly effective contraception
methods must be used.

13. Sexually active males must use a condom during intercourse while taking the drug and
for 90 days after stopping study drug and should not father a child in this period. A
condom is required to be used also by vasectomized men in order to prevent delivery of
the drug via seminal fluid.

14. Hypersensitivity to GB2064 and/or its excipients.

15. Participants unable or unwilling to comply with protocol requirements.

16. Participants related to PI/site staff.

17. Participants who have had a hematopoietic stem cell transplantation.

18. Participants who are eligible, have a donor and are willing to undergo a hematopoietic
stem cell transplantation.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/06/2026
Actual
Sample size
Target
21
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Woden Dermatology - Canberra
Recruitment postcode(s) [1] 0 0
2605 - Canberra
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Texas
Country [2] 0 0
Germany
State/province [2] 0 0
Düsseldorf
Country [3] 0 0
Germany
State/province [3] 0 0
Heidelberg
Country [4] 0 0
Germany
State/province [4] 0 0
Leipzig
Country [5] 0 0
Germany
State/province [5] 0 0
München
Country [6] 0 0
Italy
State/province [6] 0 0
Bologna
Country [7] 0 0
Italy
State/province [7] 0 0
Firenze
Country [8] 0 0
Italy
State/province [8] 0 0
Milano
Country [9] 0 0
Italy
State/province [9] 0 0
Orbassano
Country [10] 0 0
Italy
State/province [10] 0 0
Varese

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Galecto Biotech AB
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
OPIS s.r.l
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is an open label, phase IIa trial in subjects with Myelofibrosis
Trial website
https://clinicaltrials.gov/ct2/show/NCT04679870
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Richard F Schlenk, MD
Address 0 0
Universitätsklinikum Heidelberg, Germany
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04679870